; (2) illnesses related and often comorbid with Long COVID, which may include— (A) myalgic encephalomyelitis/chronic fatigue syndrome; (B) fibromyalgia; (C) postural orthostatic tachycardia syndrome and other forms of dysautonomia; (D) autoimmune diseases associated with viral triggers; (E) connective tissue diseases exacerbated or triggered by infections; (F) mast cell activation syndrome; (G) related conditions and illnesses that may affect adults, young adults, or children; and (H) other conditions, as the Secretary determines appropriate; (3) the availability, as medically appropriate, of treatment options for Long COVID and related conditions overlapping with Long COVID identified under paragraph (2); and (4) strategies for reducing the likelihood of developing Long COVID. (b) Long COVID provider education program The Secretary, in consultation with representatives from impacted communities and health care providers who treat such communities or individuals, shall develop and disseminate to health care providers, including by developing or improving continuing medical education programs that advance the education of such providers, information on Long COVID, recommended assessment tools, including how to assess patients’ functional capacity to support applications for disability benefits, and management of Long COVID and related conditions for the purpose of ensuring that health care providers remain informed about current information on Long COVID and related conditions, including information on— (1) Long COVID symptoms such as cognitive, neurological, psychiatric, gastrointestinal, respiratory, and cardiovascular symptoms; (2) myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia; (3) postural orthostatic tachycardia syndrome and other forms of dysautonomia; (4) autoimmune diseases associated with viral triggers; (5) connective tissue diseases exacerbated or triggered by infections; (6) mast cell activation syndrome